For patients, the key is preparation: confirm your plans formulary, work closely with your healthcare provider to document eligibility, and be ready to navigate step therapy or an appeal if coverage is initially denied
In the pivotal Phase 2 obesity trial (n=338, 48 weeks), the 12 mg arm achieved a mean body weight reduction of 24.2% versus 2.1% in the placebo group [1]
Your healthcare providers expertise is invaluable in making the right decision for your weight management journey
Some clinicians use TA1 offlabel to support patients with autoimmune disease, citing its ability to modulate the immune system without broad suppression
FDA for Orforglipron for the treatment of adults with obesity or overweight
Vehicle was PBS containing 0.007% polysorbate 20, 50 mM phosphate and 70 mM sodium chloride, at pH 7.4